首页> 外文期刊>Scientific reports. >Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
【24h】

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration

机译:通过DCE-MRI登记捕获的肿瘤异质性早期变化对乳腺癌新辅助化疗的治疗反应预测

获取原文
           

摘要

We analyzed DCE-MR images from 132 women with locally advanced breast cancer from the I-SPY1 trial to evaluate changes of intra-tumor heterogeneity for augmenting early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) after neoadjuvant chemotherapy (NAC). Utilizing image registration, voxel-wise changes including tumor deformations and changes in DCE-MRI kinetic features were computed to characterize heterogeneous changes within the tumor. Using five-fold cross-validation, logistic regression and Cox regression were performed to model pCR and RFS, respectively. The extracted imaging features were evaluated in augmenting established predictors, including functional tumor volume (FTV) and histopathologic and demographic factors, using the area under the curve (AUC) and the C-statistic as performance measures. The extracted voxel-wise features were also compared to analogous conventional aggregated features to evaluate the potential advantage of voxel-wise analysis. Voxel-wise features improved prediction of pCR (AUC?=?0.78 (±0.03) vs 0.71 (±0.04), p??0.05 and RFS (C-statistic?=?0.76 (?±?0.05), vs 0.63 (?±?0.01)), p??0.05, while models based on analogous aggregate imaging features did not show appreciable performance changes (p??0.05). Furthermore, all selected voxel-wise features demonstrated significant association with outcome (p??0.05). Thus, precise measures of voxel-wise changes in tumor heterogeneity extracted from registered DCE-MRI scans can improve early prediction of neoadjuvant treatment outcomes in locally advanced breast cancer.
机译:我们分析了来自I-Spy1试验的132名患有局部晚期乳腺癌的DCE-MR图像,以评估Neoadjuvant化疗后增加病理完全反应(PCR)和复发的存活(RFS)的早期预测的肿瘤内非均相的变化(NAC)。利用图像配准,计算包括肿瘤变形和DCE-MRI动力学特征的变化的体素变化,以表征肿瘤内的异质变化。使用五倍的交叉验证,分别对型PCR和RF进行逻辑回归和COX回归。在增强建立的预测因子中评估提取的成像特征,包括使用曲线(AUC)下的面积和C型统计学的功能肿瘤体积(FTV)和组织病理学和人口因子。还将提取的体素 - 明智特征与类似的常规聚集特征进行比较,以评估体素 - 明智分析的潜在优势。 Voxel-Wise特征改善了PCR的预测(AUC?= 0.78(±0.03)Vs 0.71(±0.04),p?<?0.05和RFS(C叠统计?0.76(?±0.05),Vs 0.63( ?±0.01)),p?<?0.05,而基于类似的聚集成像特征的模型没有显示出明显的性能变化(p?>?0.05)。此外,所有选定的体素明智的特征都表现出与结果的显着关联(p <?0.05)。因此,从注册的DCE-MRI扫描中提取的肿瘤异质性的精确度量可以改善局部晚期乳腺癌中新辅助治疗结果的早期预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号